SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
The hallmark of linear azol(in)e-containing peptide (LAP) biosynthesis is the formation of azol(in)e heterocycles from the nucleophilic amino acids serine, threonine, or cysteine. This is accomplished by three enzymes referred to as the B, C, and D proteins; the precursor peptide is referred to as the A protein, as in other classes. The C protein is mainly involved in leader peptide recognition and binding and is sometimes called a scaffolding protein. The D protein is an ATP-dependent cyclodehydratase that catalyzes the cyclodehydration reaction, resulting in formation of an azoline ring. This occurs by direct activation of the amide backbone carbonyl with ATP, resulting in stoichiometric ATP consumption. The C and D proteins are occasionally present as a single, fused protein, as is the case for trunkamide biosynthesis. The B protein is a flavin mononucleotide (FMN)-dependent dehydrogenase which oxidizes certain azoline rings into azoles. The B protein is typically referred to as the dehydrogenase; the C and D proteins together form the cyclodehydratase, although the D protein alone performs the cyclodehydration reaction. Early work on microcin B17 adopted a different nomenclature for these proteins, but a recent consensus has been adopted by the field as described above.
In 2005, the FDA added a boxed warning concerning pediatric suicidal behavior to all antidepressants, including sertraline. In 2007, labeling was again changed to add a warning regarding suicidal behavior in young adults ages 18 to 24.
=== Absorption === The oral bioavailability of testosterone is very low. The bioavailability of oral testosterone undecanoate is 3 to 7%. Topical testosterone gels have a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. The bioavailability of testosterone by subcutaneous implant is virtually 100%. The bioavailability of drugs that are administered intramuscularly is generally almost 95%.
Some plants such as willow trees and poplars have been found to clean both lead and cadmium from soil. Typical background concentrations of cadmium do not exceed 5 ng/m3 in the atmosphere; 2 mg/kg in soil; 1 μg/L in freshwater and 50 ng/L in seawater. Concentrations of cadmium above 10 μg/L may be stable in water having low total solute concentrations and pH and can be difficult to remove by conventional water treatment processes.
In addition to formalin, other chemical fixatives have been used. But, with the advent of immunohistochemistry (IHC) staining and diagnostic molecular pathology testing on these specimen samples, formalin has become the standard chemical fixative in human diagnostic histopathology. Fixation times for very small specimens are shorter, and standards exist in human diagnostic histopathology.
Sources: en.wikipedia.org
The anticonvulsant properties of lorazepam and other benzodiazepines may be, in part or entirely, due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by the benzodiazepine effect of slowing recovery of sodium channels from inactivation to deactivation in mouse spinal cord cell cultures, hence prolonging the refractory period.
After Santiesteban Prats informed Viñas Alonso about the conversation, the Grand Master and the Grand Commander disagreed on where the money should be kept, but it did stay in the Grand Master's office. According to a report by Urquía Carreño, on January 5, 2024, at the offices of the National Masonic Temple, Grand Treasurer Airán Cervera pulled Urquía Carreño aside, and asked him if they could discuss something in private. They went up to the roof, where Airán Cervera told Urquía Carreño that the safe was gone, probably stolen. Urquía Carreño, according to his report, kept this information to himself. At 10:15am on January 9, 2024, the Director of Llansó called Grand Commander Viñas Alonso to inform him that they were in the midst of a food shortage. The two men decided to withdraw 1,000 dollars from the vaults of the Grand Lodge to buy food for the residents. At around noon, Viñas Alonso called Urquía Carreño to inform him that Viñas Alonso would be joined by the Treasurer of the Board of Trustees, Ernesto Valdés García, the Secretary of the Board of Trustees, Frank E. Quevedo Martín, and the Director of the retirement home, Raúl Acosta to come to the vault and withdraw 1,000 dollars. After being informed of the situation, Grand Master Urquía Carreño said that the elevator in his office was broken, and that Urquía Carreño would bring the money to the offices of the Supreme Council. Grand Commander Viñas Alonso refused, citing the rules. Urquía Carreño said that he understood, and would call later to tell Viñas Alonso what time they could come by the office.
====== Pain medicine ====== To train in the add-on specialty of pain medicine a physician must first be a specialist in one of the pediatric class specialties, one of the independent class specialties (excluding clinical pharmacology, clinical genetics, forensic medicine, and social medicine), one of the internal medicine class specialties, one of the surgical class specialties, one of the neurological class specialties (excluding clinical neurophysiology) or one of the psychiatric class specialties.
== Chemical structure == The synthesis of CP-154,526, a non-peptide antagonist of the CRH1 receptor, was first described in 1997. Antalarmin is a close analog that is highly structurally similar and has been shown to be easier to synthesize. The findings from several chemical, pharmacokinetic and pharmacological studies indicate that the two compounds possess very similar properties.
=== Recreational use === It was said in the mid-1970s that use of nutmeg for recreational purposes was almost exclusively confined to the United States. It was said to be sought as an alternative to other preferred hallucinogens such as LSD and cannabis. The drug has frequently been used by incarcerated people in prisons. This has led to availability of nutmeg in prison kitchens being restricted.
Sources: en.wikipedia.org
=== Medical informatics, AI, and multimodal modeling === Several studies have focused on data standards and artificial intelligence using Truveta data. A 2023 preprint titled Truveta Mapper: A Zero-shot Ontology Alignment Framework presented a methodology for aligning biomedical ontologies using zero-shot learning, as a tool that could support data interoperability for health systems. A 2025 study published in Studies in Health Technology and Informatics explored structured large language model (LLM) augmentation for clinical information extraction, assessing its performance and potential for healthcare data analysis. In 2025, a study in Radiology Advances developed "XComposition", a multimodal deep-learning model that uses chest radiographs and clinical data to estimate body composition, as an application of large health-system data for medical imaging research.
Another example is the Born (ionic) model of the ionic lattice. The first term in the next equation is Coulomb's law for a pair of ions, the second term is the short-range repulsion explained by Pauli's exclusion principle and the final term is the dispersion interaction term. Usually, a simulation only includes the dipolar term, although sometimes the quadrupolar term is also included. When nl = 6, this potential is also called the Coulomb–Buckingham potential.
=== Gradual dissolution === In March 2002, the governments of Montenegro and Serbia, along with the Federal Republic of Yugoslavia (FRY), signed the Accord on Principles in Relations between Serbia and Montenegro (commonly known as the Belgrade Agreement), which outlined the restructuring of their mutual relations. This agreement led to the adoption of the Constitutional Charter of Serbia and Montenegro on 4 February 2003, officially transforming the FRY into the State Union of Serbia and Montenegro and formally retiring the name "Yugoslavia" after 74 years. The Constitutional Charter included a provision allowing either republic to hold a referendum on independence after a three-year transition period. On 21 May 2006, Montenegro held such a referendum. The final results showed that 55.5% of voters supported independence, narrowly surpassing the 55% threshold set by the European Union for the referendum's validity. Voter turnout was 86.5%. Following the referendum, Montenegro's parliament formally declared independence on 3 June 2006. Subsequently, on 5 June 2006, Serbia's parliament did the same, effectively dissolving the union and marking the final chapter in the disintegration of the former Yugoslavia.
=== Parallel MRI === It takes time to gather MRI data using sequential applications of magnetic field gradients. Even for the most streamlined of MRI sequences, there are physical and physiologic limits to the rate of gradient switching. Parallel MRI circumvents these limits by gathering some portion of the data simultaneously, rather than in a traditional sequential fashion. This is accomplished using arrays of radiofrequency (RF) detector coils, each with a different 'view' of the body. A reduced set of gradient steps is applied, and the remaining spatial information is filled in by combining signals from various coils, based on their known spatial sensitivity patterns. The resulting acceleration is limited by the number of coils and by the signal to noise ratio (which decreases with increasing acceleration), but two- to four-fold accelerations may commonly be achieved with suitable coil array configurations, and substantially higher accelerations have been demonstrated with specialized coil arrays. Parallel MRI may be used with most MRI sequences. After a number of early suggestions for using arrays of detectors to accelerate imaging went largely unremarked in the MRI field, parallel imaging saw widespread development and application following the introduction of the simultaneous acquisition of spatial harmonics (SMASH) technique in 1996–7. The sensitivity encoding (SENSE) and generalized autocalibrating partially parallel acquisitions (GRAPPA) techniques are the parallel imaging methods in most common use today.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.